TP53 Mutant Cell Lines Selected for Resistance to MDM2 Inhibitors Retain Growth Inhibition by MAPK Pathway Inhibitors but a Reduced Apoptotic Response

Cancer Cell International - United Kingdom
doi 10.1186/s12935-019-0768-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors

Cancer Cell
Cancer ResearchOncologyCell Biology
2014English

Author Correction: PAK Signalling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas

Nature
Multidisciplinary
2018English

Period2 Downregulation Inhibits Glioma Cell Apoptosis by Activating the MDM2-TP53 Pathway

Oncotarget
Oncology
2016English

Inhibitors of Pan-Pi3k Signaling Synergize With BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

Frontiers in Oncology
Cancer ResearchOncology
2015English

Resistance to Telomerase Inhibition by Human Squamous Cell Carcinoma Cell Lines

International Journal of Oncology
Cancer ResearchOncology
2011English

Resistance to PARP Inhibitors by SLFN11 Inactivation Can Be Overcome by ATR Inhibition

Oncotarget
Oncology
2016English

mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even After Acquiring Resistance by HGF

PLoS ONE
Multidisciplinary
2013English

Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2019English

A Mutant Form of Human Protein Farnesyltransferase Exhibits Increased Resistance to Farnesyltransferase Inhibitors

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1999English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy